A 38-year-old woman was admitted to our hospital because of amenorrhea, multiple bone fractures, and a Cushingoid appearance. Endocrinological investigations revealed that she had co-existing Cushing's disease and prolactinoma, with a serum level of prolactin (PRL) at 1,480 ng/mL, corticotropin (ACTH) at 81.3 pg/ mL, and cortisol at 16.6 μg/dL. Due to the lack of indication for transsphenoidal surgery, cabergoline monotherapy was initiated. A 6-month course of treatment resulted in only subtle amelioration of hypercortisolism, while hyperprolactinemia was dramatically improved. In 5 cases of bihormonal (ACTH/PRL) pituitary macroadenoma reported in the English literature, 2 were initially treated with dopaminergic agonists with substantial effectiveness for both PRL and ACTH. We herein report an extremely rare case of bihormonal macroadenoma in which only PRL was responsive to treatment.
pramide, rabeprazole, and furosemide at admission.
An initial physical examination showed an apparent moon face and central obesity. Her blood pressure was 138/72 mmHg, pulse was 98 beats per minute, body temperature was 37.0 , body weight was 55.3 kg, height was 144 cm, and body mass index was 26.6. She had hirsutism and pitting edema on the lower legs, while skin stria was not present. Breast development was Tanner stage 5. Other physical examination findings were unremarkable.
Laboratory examination results are shown in Table 1 . The total white blood cell (WBC) count was 8,010/μL, and consisted of an elevated neutrophil fraction and decreased lym-phocyte and eosinophil fractions. Mild hypoproteinemia and hypoalbuminemia were seen. The serum alkaline phosphatase (ALP) level was elevated and serum concentrations of hepatic enzymes were normal, except for mildly elevated γ-glutamyl transpeptidase (γ-GTP). The renal function was normal, while hypernatremia and hypokalemia were found. The serum concentrations of calcium and phosphorus were normal. Neither dyslipidemia nor diabetes was present. The bone mineral density was markedly decreased (lumbar: Tscore -3.7 SD, Z score -3.6 SD, femoral neck: T-score -4.0 SD, Z-score 3.6 SD) and a remarkably high value for tartrate-resistant acid phosphatase 5b (TRACP-5b) indicated Endocrinological investigations revealed an elevated serum concentration of prolactin (PRL) to 1,954 ng/mL, which only marginally decreased to 1,480 ng/mL at 1 month after cessation of risperidone and metoclopramide. The plasma ACTH level was elevated to 81.3 pg/mL and plasma cortisol level to 16.6 μg/dL (within the normal range), while dehydroepiandrosterone sulfate was mildly elevated to 269 μg/ dL. Urinary free cortisol excretion ranged from 188-309 μg/ day. A thyrotropin releasing hormone (TRH) test showed that the serum level of PRL was marginally affected by intravenous administration of 200 μg of TRH (Table 2) , while it was significantly suppressed from 1,878 to 687 ng/mL (3 hours) and 268.7 ng/mL (6 hours) in response to an oral administration of 2.5 mg of bromocriptine, indicating that dopamine agonists could be a promising therapeutic option. Meanwhile, in overnight dexamethasone suppression tests, the levels of ACTH and cortisol were not suppressed by either 0.5 or 8 mg of dexamethasone.
Although the patient had regularly taken carbamazepine, which was reported to possibly cause false positive test results because of accelerated metabolism of dexamethasone (1), the abnormally high midnight levels of ACTH and cortisol indicated the presence of secondary hypercorticism ( Table 2) . Because of a possible effect of carbamazepine, it was difficult to identify which of two entities, Cushing's disease (CD) or ectopic ACTH syndrome, was more likely. Corticotropin releasing hormone (CRH) and desmopressin challenge test results showed equivocal findings of a moderate response of ACTH (87.4 to 137.0 pg/mL in response to CRH; 59.7 to 70.2 pg/mL in the desmopressin test). Responses of thyroid stimulating hormone (TSH) to TRH (Table 2) and of gonadotropin (Gn) to Gn releasing hormone (GnRH) were normal. The growth hormone (GH) level was somewhat elevated following a 75-g oral glucose tolerance test ( Table 2 ), suggesting abnormal regulation of GH secretion. However, plasma insulin-like growth factor-1 (IGF-1) was 94 ng/mL, which was slightly below the normal range (103-254 ng/mL). Abdominal CT scanning detected a hepatic hemangioma and ovarian tumor, but not adrenal hyperplasia. To confirm those findings, we conducted inferior petrosal sinus (IPS) sampling. Right and left IPS serum samples revealed a remarkable elevation of basal ACTH to 253 and 333 pg/mL, respectively, as compared to the basal level in the inferior vena cava of 70.2 pg/mL. CRH challenge was not possible, as the patient was not able to keep still for an adequate time during the procedure due to mental retardation. The results of IPS sampling are shown in Table 3 . According to these results, we concluded that the patient had both CD and prolactinoma.
We discussed with neurosurgeons regarding the indications for transsphenoidal surgery and concluded that it would be difficult to perform, as the pituitary tumor was adjacent to the right internal carotid artery and mental impairment would increase the risk during perioperative management. Therefore, we considered drug therapy to be more feasible for our patient. A previous case of concomitant CD and prolactinoma was successfully treated with cabergoline (1). Thus, we started cabergoline therapy at 0.25 mg/ week, and then increased the dose to 0.5 mg/week after 5 months. After increasing the dose, her parents noted aggravated irritation with increasing offensive behavior. We considered that the change in mood was a related side effect of cabergoline and refrained from further dosage increases.
Six months after starting cabergoline, the patient was readmitted to our hospital for a close endocrinological evaluation of the effectiveness of treatment ( Table 2 ). The Cushingoid appearance was not remarkably improved. As for hyperprolactinemia, the serum level of PRL was dramatically decreased to 32.3 ng/mL and we observed a significant response to intravenous administration of 200 μg of TRH. On the other hand, only a subtle effect was observed in regard to CD. The serum level of ACTH was rather suppressed, though still high, while the circadian rhythm of ACTH and cortisol remained disturbed. Urinary free cortisol excretion also remained higher than the normal range. Overnight 0.5and 8-mg dexamethasone tests again showed no adequate suppression, though the serum cortisol level after 8 mg of dexamethasone was decreased to half of the basal level. There was not a significant change in the size of the pituitary tumor (27 mm) observed in follow-up MRI, while a new small hemorrhagic lesion was noted inside the tumor (Fig. 1) .
During the second admission, the mental status of the patient was aggravated and she demonstrated a short temper. This forced us to discontinue cabergoline therapy with the start of risperidone, which was associated with reelevation of the plasma PRL level up to 2,000 ng/mL. Thereafter, with the help of psychiatrists to ease her mental status, cabergoline therapy was reinitiated and the dose increased up to 1 mg/week, which resulted in suppression of the plasma PRL levels (Fig. 2) . However, the clinical signs of CD and serum cortisol values did not show improvement. Seven months after initiating cabergoline, metyrapone was started at a dose of 250 mg/day and gradually increased to 1,000 mg/day within 6 months, yet hypercorticism remained uncontrollable. The patient often complained about taking the metyrapone capsules and had been receiving training to take the medicine. Despite recommendations of TSS to the family according to continuous discussions with neurosurgeons, her parents were reluctant due to the risks associated with surgery.
Discussion
We herein present a rare case of concomitant CD and prolactinoma. Drug-induced hyperprolactinemia could be excluded in our patient, since discontinuation of risperidone for 1 month resulted in only a marginal decrease in the serum prolactin level. Moreover, the blood level of PRL was >1,000 ng/mL, while risperidone, the most notable drug for elevating PRL secretion, has been reported to increase to more than 400 ng/mL (2) . Amenorrhea in our patient had never been closely examined until 38 years of age, thus it is possible that underestimated hyperprolactinemia had been present for many years prior. Even though the presence of menarche was not clear, a physical examination revealed normal signs of puberty (breast development, normal axillary and pubic hair), indicating that she had passed through at least the earlier stages of puberty. Thus, a diagnosis of congenital disease such as Turner syndrome with cooccurrence of possible primary amenorrhea and short stature was unlikely. The endocrinological and radiological examinations and the clinical course suggested a mixed pituitary adenoma secreting both ACTH and PRL. One of the intriguing features of the present case is that even though cabergoline treatment markedly suppressed and normalized the serum PRL level, the levels of ACTH and cortisol in the serum, as well as the size of the pituitary adenoma, were not diminished during the course of treatment.
In the German Registry of Pituitary Tumors (3), immunohistochemical examinations of 3,403 pituitary adenomas revealed that 66.5% were monohormonal, 6.5% were bihormonal for GH and PRL, 1.3% were plurihormonal, and 25.6% did not express any hormones. Additionally, with im- proved immunostaining techniques using monoclonal antibodies, the incidence of plurihormonal adenomas was lower than expected (3, 4) . Plurihormonal adenoma type I corresponds to GH cell adenomas with positive expression of TSH, and often that of follicle stimulating hormone (FSH), luteinizing hormone (LH), or PRL, in addition to GH. Type II is structurally very similar to a gonadotrope adenoma, though it expresses either TSH, GH, or PRL, in addition to FSH and LH. The silent subtype 3 adenoma is immunoreactive not only for GH, PRL, and TSH, but also for other hormones. Bihormonal pituitary adenomas secreting PRL/ ACTH are extremely rare and, to the best of our knowledge, only 5 cases have been reported in the English literature which showed clinical signs and endocrinological features of CD and hyperprolactinemia (Table 2) (5-9).
On the other hand, the incidence of double pituitary adenomas was shown to be as low as 2.6% in an unselected surgical series of 117 patients with pituitary adenoma (10) . The majority of patients with double pituitary adenomas have been documented as case reports and were recently summarized (11) . Among a series of 60 cases of multiple pituitary adenomas, the combination of ACTH and PRL was most common, with a prevalence of 33% (11) . In another registry of CD patients, 13 (3.3%) of 660 cases were found to have histologically confirmed multiple adenomas, 9 (1.36%) of which were diagnosed with a prolactinoma according to the immunocytochemical findings. Of those, preoperative hyperprolactinemia was demonstrated in only 3 (0.45%) of 660 cases, including 1 case with multiple endocrine neoplasia (MEN) type 1 (10) . Thus, clinically apparent CD plus hyperprolactinemia due to double pituitary adenomas appears to be extremely rare.
In the present case, MRI revealed a single large pituitary tumor, though a histological examination was not possible. It is natural to consider that we should not negate the possibility of the co-existence of a second pituitary adenoma undetectable by MRI. However, the PRL level generally correlates with the tumor size and a level higher than 200 ng/mL nearly always indicates a macroprolactinoma (12) . Because our patient had an extremely high PRL level (1,840 ng/mL), the existence of a MRI-undetectable microadenoma appears to be unlikely. Nevertheless, though a bihormonal pituitary adenoma secreting ACTH/PRL is the most likely pathology, we cannot negate the possibility that this patient has a macroPRLoma and a MRI-undetectable microACTHoma, with the size of the PRLoma causing its resistance to cabergoline therapy. In our patient, cabergoline treatment for 6 months markedly reduced the serum PRL level to the upper normal range (from 1,840 to 32.3 ng/mL) without a reduction in the tumor size. Dopamine agonists used as primary therapy for a prolactinoma have been shown to be effective (13, 14) and cabergoline therapy has been shown to decrease the tumor mass at various rates (30-61% for >80% mass reduction, 79% for >25% mass reduction) (15) (16) (17) . Although PRL normalization was found to be significantly related to the occurrence of tumor shrinkage (18) , there have been some cases reported with less remarkable mass reduction (<25%), despite the serum PRL level being significantly lowered (13) . In a case report of a large prolactinoma, cabergoline treatment led to substantial tumor shrinkage without any decrease in the serum PRL level (19) . These case presentations suggest that hormonal and mass responses to cabergoline may not be associated. In our patient, a quick temper and mental aggravation at the second admission forced us to discontinue cabergoline therapy, which was associated with a rapid elevation of the plasma PRL level to as high as 2,000 ng/mL. This rapid rise in PRL suggests that cabergoline therapy at 0.5 mg/week was not sufficient to completely reduce the tumor mass. It is also possible that the bihormonal features of the tumor cells might be associated with the lack of effect of cabergoline on the tumor size.
Among the 5 reported cases of pituitary macroadenoma with ACTH/PRL overproduction (Table 4) , the initial treatments in 2 were neurosurgical resection (5, 7) , while the other 3 received treatment with dopamine D2 receptor agonists (6, 8, 9) . For patients with CD alone, though dopamine D2 receptor (D2R) agonists have been proposed in recent years to be the first choice for treatment (20) (21) (22) , the longterm clinical efficacy of cabergoline (30-40%) is not attractively high. As for ACTH/PRL bihormonal pituitary adenomas, a young boy was successfully treated with bromocriptine for more than 6 months, which resulted in an impressive reduction in the tumor size, lowering of the prolactin level to within a normal range, and regression of both the clinical and biochemical signs of hypercortisolism (6) . Another case report of a 31-year-old man affected with a macroprolactinoma associated with CD showed that normalization of the PRL level and disappearance of the clinical and biochemical features of CD were obtained after administration of cabergoline (9) . In a third case, a 42-yearold woman showed an atypical clinical course of initial macroprolactinoma (PRL 12,720 μg/L, huge tumor with extrasellar extension) and a 1-year period of dopaminergic treatment that led to PRL normalization and tumor shrinkage, which was followed by a clinical presentation of hypercortisolism (urinary cortisol 1,000 μg/day, ACTH 200 ng/L) and surgical cure of hypercortisolism with persisting hyperprolactinemia (8) . The immunocytochemistry findings of the resected tumor revealed a mixed ACTH-PRL adenoma. Thus, even though a quite limited number of ACTH/PRL mixed pituitary adenomas have been treated with dopaminergic agonists, 2 of those cases showed impressive responses in regard to the clinical and biochemical signs of hypercortisolism and hyperprolactinemia, as well as a remarkable reduction in the tumor size. Our case represents a unique pattern of responsiveness to cabergoline treatment. In contrast to the remarkable decrease in the serum PRL level, no overproduction of ACTH and cortisol, reduction in the tumor size, or significant clinical improvement were observed after 6 months of treatment.
We cannot rule out the possibility that the dose of cabergoline (1.0 mg/week) was not sufficient to suppress CD, since long-term efficacy was achieved with mean doses of 2.1 and 3.5 mg/week in previous reports (21, 22) . However, in those reports, short-term efficacy was established with much lower doses in patients who responded to cabergoline and it is not clear whether initially nonresponsive patients will subsequently respond to a higher dose. A more likely explanation may be that PRL-and ACTH-producing cells exist in 2 distinct populations in a single adenoma, as in 2 previously reported cases (5, 7) . A follow-up MRI examination of our patient showed a partial hemorrhagic area in the pituitary tumor, which may have been related to PRLproducing clusters of cells necrotized by cabergoline therapy (23) . In contrast, Yamaji et al. reported that mild hyperprolactinemia was observed in 6 (23%) of 26 CD patients and suggested that concomitant production and secretion of PRL from a corticotroph adenoma in those cases (24) . Although the histopathological data are not available, this type of histology may apply to cases that show substantial responsiveness to dopaminergic treatments (6, 9) . Finally, another rare possibility is the presence of an ectopic pituitary ACTH-producing adenoma derived from the sphenoid sinus (25) together with an adjacent pituitary macroprolactinoma. In our patient, MRI findings revealed that the mass extended preferably to the sphenoid sinus and did not have a suprasellar orientation. The finding of less responsiveness to a high-dose dexamethasone-suppression test in our case may also be consistent with an ectopic (nonpituitary) source, though it is important to take into account the influence of carbamazepine treatment already given, which may have attenuated the action of high-dose dexamethasone (1). In addition, Suzuki et al. (26) performed a literature review and found a variable response to dex-amethasone suppression in multiple cases.
In summary, we encountered an extremely rare patient with clinical features of CD and prolactinoma. Unlike 2 previously reported cases, hypercortisolism and the tumor size were uncontrollable with cabergoline, whereas hyperprolactinemia was completely normalized. Further investigations are necessary to unravel the mechanisms of the pathogenesis of this rare bihormonal pituitary adenoma and reveal predictors for the efficiency of dopaminergic agonists.
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